(vianews) - the market ended the session with nanobiotix (nano.pa) rising 11.21% to €4.91 on thursday, after two successive sessions in a row of losses. cac 40 rose 0.55% to €7,137.43, after three consecutive sessions in a row of losses, on what was a somewhat bullish trend exchanging session today.
nanobiotix's last close was €4.42, 37.82% under its 52-week high of €7.10.
about nanobiotix
nanobiotix s.a., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. its lead product candidate is nbtxr3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. nanobiotix s.a. has a partnership with lian oncology limited to develop and commercialize nbtxr3 in greater china, south korea, singapore, and thailand. nanobiotix s.a. was incorporated in 2003 and is headquartered in paris, france.
earnings per share
as for profitability, nanobiotix has a trailing twelve months eps of €-1.64.
volume
today's last reported volume for nanobiotix is 254740 which is 2.64% above its average volume of 248183.
revenue growth
year-on-year quarterly revenue growth grew by 159.6%, now sitting on 4.78m for the twelve trailing months.
stock price classification
according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, nanobiotix's stock is considered to be overbought (>=80).
yearly top and bottom value
nanobiotix's stock is valued at €4.91 at 22:34 est, way under its 52-week high of €7.10 and way above its 52-week low of €1.61.
more news about nanobiotix (nano.pa).